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Summary
Background: Multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic problem in
many parts of the world, necessitating the inclusion of second-line anti-tuberculosis drugs in
specific treatment regimens.
Methods: We studied the susceptibility of 69 MDR Mycobacterium tuberculosis isolates from
Rwanda to second-line drugs by the BACTEC 460 method.
Results: The results showed that 62 (89.9%) were resistant to rifabutin while a low rate (4.3%) of
resistance was registered for ofloxacin; there was one case (1.4%) of resistance each for para-
aminosalicylic acid, kanamycin, ethionamide, and clarithromycin.
Conclusions: This information is important for devising an appropriate treatment regimen for
MDR-TB patients in order to stop the spread of MDR strains and contain the acquisition of
additional drug resistance in Rwanda.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The global rates of tuberculosis (TB) continue to rise, as do
rates of drug-resistant TB. Exact rates of drug resistance are
unknown, but the World Health Organization/International
Union Against TB and Lung Disease (WHO/IUATLD) global* Corresponding author. Tel.: +32 3 247 64 73; fax: +32 3 247 63 33.
E-mail address: alainenyaruhirira@hotmail.com (A. Umubyeyi).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2007.05.003project on anti-TB drug resistance surveillance has con-
ducted over 77 surveys and has noted high rates (>6.5%)
of multidrug-resistant (MDR) TB (i.e., strains resistant to at
least isoniazid (H) and rifampin (R), the two most potent
drugs and mainstay of anti-TB treatment1) in some areas of
the world, such as Eastern Europe.2 In resource-poor areas,
inconsistent drug supply and weak TB-control infrastructure
can lead to a vicious cycle of inadequate treatment and the
generation and transmission of MDR-TB strains.3Published by Elsevier Ltd. All rights reserved.
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In 2003, the annual incidence of new sputum smear-positive
cases was estimated to be 161/100 000 population and the
prevalence was 664/100 000 population. The TB incidence
in Rwanda has doubled over the last decade mainly due to
the impact of the human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) epidemic.4 A
recent national survey on drug-resistant TB indicated a
relatively high prevalence of MDR with 3.9% among new
cases and 9.4% among retreatment cases.5 However, this
survey did not systematically examine resistance to second-
line drugs.
Cure rates for MDR-TB patients are low when standard
first-line DOTS (directly observed therapy short course) is
administered, but with the inclusion of second-line drugs in
adapted treatment regimens, treatment success rates vary
from 48% to more than 80% of patients being cured or
probably cured.6 MDR-TB patient management is often car-
ried out using the DOTS-Plus strategy,6 and opportunities to
treat MDR-TB in low-resource countries are now available
through the Global Fund to Fight AIDS, TB, and Malaria and
theGreen Light Committee for Access to Second-line Anti-TB
Drugs. MDR-TB treatment can be based on the individual
results of susceptibility testing to second-line drugs (indivi-
dualized treatment), or can be standardized, i.e., the same
regimen for all MDR-TB patients within a specific TB pro-
gram.
In vitro susceptibility testing to second-line drugs is not
well standardized. In addition, individual testing is difficult
and expensive to organize in many settings, and results are
only available after a few weeks. Alternatively, a population-
based estimation of drug resistance to second-line drugs by
analyzing a sample of MDR strains can be the basis for a
standardized MDR-TB treatment scheme in a specific region.7
In the present study, we aimed at performing second-line
drug testing for MDR-TB patients resulting from a conveni-
ence sample, in order to provide specific information that can
contribute to the development of an empiric second-line
treatment regimen for Rwanda.Materials and methods
Study area and population
Rwanda is a small landlocked country in East Africa with 11
provinces and an estimated population of 8.6 million. The
National Tuberculosis Control Program (NTP) of Rwanda was
created in 1990 and has applied the DOTS strategy since its
inception.4 After the 1994 war, which disorganized the health
system completely, the TB program expanded progressively
to reach full DOTS coverage in 2000. There are four reference
hospitals, 35 district hospitals, and 133 health centers
(including nine prison dispensaries) that assure TB detection
under the Ministry of Health (MOH). Diagnosis of TB in the NTP
depends largely on quality-controlled sputum smear exam-
ination. Treatment of TB patients is available in most parts of
the country through DOTS. The current treatment regimen is
2(RHZE)7/4(RH)3 for new cases and 2(RHZE)7S7/1(RHZE)7/
5(RHE)3 for retreatment cases (R = rifampin, H = isoniazid,
Z = pyrazinamide, E = ethambutol, and S = streptomycin;
numbers before the letters indicate the duration in monthsof the phase of treatment; subscript numbers indicate the
number of times the drug is taken each week).4
Sampling of MDR-TB
This study was undertaken prospectively in seven diagnostic
centers in four cities in Rwanda, i.e., Kigali with the
highest incidence (331.3/100 000), followed by Butare
(129/100 000), Kibungo (80/100 000), and Ruhengeri
(23.9/100 000).4 This study was approved by the Ethics
Review Board at Centre Hospitalier Universitaire de Kigali
(CHUK), Rwanda.
From September 2002 to March 2005, all smear-positive
pulmonary TB patients were systematically included in the
study, and a standard WHO questionnaire was used to discern
the history of disease, the results of HIV serology, and
demographic data.5 Categorizing of new and previously-trea-
ted patients was ensured by strict adherence to the standard
WHO/IUATLD definitions and by cross-checking with the
patient treatment records where available.1
Drug-susceptibility testing (DST) identified 69 MDR-TB
cases (35 new and 34 previously treated cases) among 710
smear-positive pulmonary TB patients from these four set-
tings. New patients were defined as patients who had never
received anti-TB drugs or had received them for less than
1 month. Relapse was defined as recurrence of disease in a
patient previously treated for TB who had been declared
cured or who had completed treatment prior to becoming
smear-positive again. Failure was defined as a sputum-posi-
tive finding in a patient who had been receiving treatment for
at least 5 months.Identification of strains and drug-susceptibility
testing
All sputum samples were mixed with 1% cetylpyridinium
chloride (CPC) as transportation medium. The samples were
collected on a weekly basis from health districts and trans-
ported to the National Reference Laboratory (NRL) in Kigali
for analysis. Every sputum sample was accompanied by a
shipment form that contained information on the date of
sputum collection, sample number, treatment history of the
case (new or retreatment), and the quantified result of
microscopy examination. Upon receipt at the NRL, each
sample was cultured on Lo¨wenstein—Jensen (LJ) medium
after decontamination using the Petroff procedure.8 The
cultures were incubated at 37 8C and read weekly for growth
for a maximum duration of 10 weeks. Primary cultures that
resembled Mycobacterium tuberculosis were sent to the
Microbiology Laboratory, St Pierre Hospital, Belgium for spe-
cies identification and DST.
All clinical isolates were identified as M. tuberculosis
using standard microbiological tests and the 16S rRNA hybri-
dization technique (AccuProbe; Gen Probe, San Diego, CA,
USA).9
DST to the first-line anti-TB drugs was performed by the
radiometric BACTEC 460 method (Becton Diagnostic Systems,
Sparks, MD, USA) (E 5 mg/ml; H 0.2 mg/ml; R 2 mg/ml, and
S 4 mg/ml).8,10 The isolates were stored at 70 8C, and all
MDR isolates were inoculated on LJ medium and cultured at
37 8C for 3 weeks prior to second-line drug testing by BACTEC
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Table 1 Drug resistance patterns to second-line drugs among MDR-TB isolates according to case category. Susceptibility was
determined using the BACTEC 460 method
Second-line drug Number of resistant isolates according to patient category (%) Total number of
resistant isolates (%)
New cases Previously treated cases
Relapse Failure
Kanamycin 1 (2.85) 0 0 1 (1.4)
Clarithromycin 0 0 1 (3.6) 1 (1.4)
Ethionamide 1 (2.85) 0 0 1 (1.4)
PAS 0 0 1 (3.6) 1 (1.4)
Ofloxacin 1 (2.85) 1 (16.7) 1 (3.6) 3 (4.3)
Rifabutin 32 (91.4) 5 (83.3) 25 (89.3) 62 (89.9)
Total 35 6 28 69
MDR-TB, multidrug-resistant tuberculosis (resistance to at least isoniazid and rifampin); PAS, para-aminosalicylic acid.
Table 2 Breakdown of first-line and second-line drug-resis-
tance patterns for 69 MDR-TB
Pattern of resistance to first- and
second-line drugs
Number of
isolates (%)
HR 7 (10.1)
HRE + RFB 5 (7.2)
HRS + RFB 5 (7.2)
HRES + RFB 47 (68.1)
HRES + RFB + OFX 3 (4.3)
HRES + RFB + CLA + PAS 1 (1.5)
HRES + RFB + KM + ETH 1 (1.5)
H, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; RFB,
rifabutin; OFX, ofloxacin; KM, kanamycin; PAS, para-aminosa-
licylic acid; CLA, clarithromycin; ETH, ethionamide.460 using the following concentrations: kanamycin (KM)
20 mg/ml, rifabutin (RFB) 1 mg/ml, para-aminosalicylic acid
(PAS) 0.5 mg/ml, clarithromycin (CLA) 4 mg/ml, ethionamide
(ETH) 2.5 mg/ml, and ofloxacin (OFX) 1 mg/ml. The choice of
the drugs was based on the practical needs of the TB control
program in Rwanda; these drugs are those planned for use in
the treatment of patients with MDR-TB. Drug concentrations
were adapted from Walter and Heilmeyer11 for the BACTEC
460 method based on the mean maximum blood levels that
can be reached in a patient and on data obtained with
specific drug-resistant reference strains. External quality
assessment organized by the Pasteur Institute of Brussels
yielded sensitivities and specificities of 100% respectively
for ETH, OFX, KM, and RFB. Internal quality control of
first-line DST was ensured by testing 15 MDR-TB isolates on
two different occasions, and external quality control by
participating biannually in a national quality control orga-
nized by the Pasteur Institute of Brussels. Results of internal
identification and DSTwere concordant for all isolates, and a
100% specificity and sensitivity were obtained for H, R, and E
in the external assessment.
Data management and analysis
Data were double-entered using the Statistical Package for
Social Sciences (SPSS version 11.5) software on a weekly basis
during the inclusion period. These data were later linkedwith
DSTresults from the St Pierre laboratory. Both data sets were
compared using EpiInfo version 6.04d and cleaned by verify-
ing the paper-based questionnaires, sample-transportation
forms, and DST results. Analysis was done according to
WHO/IUATLD recommendations. A p value <0.05 was
considered significant.
Results
From January 2002 to September 2005, all notified smear-
positive (new and retreatment) cases were enrolled in the
study and followed-up for treatment outcome. Results of
first-line drug resistance have been previously published,12
and will thus not be discussed here. In summary, a total of 710
cases resident in the four epidemiological field sites were
notified and 644 (90.7%) of them yielded a positive cultureand valid DST results. Four hundred and eighty-three (75%)
were new TB cases while 161 (25%) were previously treated
TB cases. The majority (56.8%) were males giving a sex ratio
of 1.3:1. The mean age of the patients was 32.1  11.2 years.
Phenotypic DST classified 514 (79.8%) as being pan-sus-
ceptible to first-line anti-TB drugs, whereas 55 (8.5%) were
resistant to one or more drugs but not MDR, and 75 (11.6%)
were MDR. The MDR-TB rate was 7% among new cases and
25.5% in retreated cases.
After storage at 70 8C and subsequent sub-culturing,
only 69 of 75 MDR-TB isolates (with 35 strains from new cases
and 34 from retreatment patients) were available for second-
line DST. General susceptibility patterns according to the
case categories are presented in Table 1. Resistance to RFB
was high (89.9%), both in new (91.4%) and retreatment
(88.2%) cases. Ofloxacin resistance reached 4.3% among all
MDR-TB cases, and even 16.7% among relapse cases, although
this represents only a single case. Resistance to KM, PAS, ETH,
and CLA was very low (1.4% each).
Combined resistance patterns to first- and second-line
drugs per patient are presented in Table 2. Seven (10.1%)
MDR-TB cases showed no resistance to second-line drugs,
57 (82.6%) showed resistance to a single second-line drug
(RFB), whereas five (7.2%) MDR-TB patients showed resis-
tance to two or more second-line drugs (including RFB).
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not observed.Discussion
The present study on second-line drug resistance among MDR-
TB isolates in four regions of Rwanda was initiated out of
practical necessity. The current relatively high burden of
MDR-TB in Rwanda necessitates the development of an effec-
tive second-line drug treatment regimen. Data on second-line
drug resistance are useful in devising an effective treatment
regimen as this permits the selection of drugs with a low
resistance rate in order to obtain good cure rates and avoid
acquisition of additional resistance to second-line drugs.
Overall, results were encouraging in that all patients were
susceptible to at least two of the different second-line drugs
tested.
Resistance to RFB was present in 89.9% of the MDR-TB
isolates, reflecting the expected proportion of cross-resis-
tance with rifampin.6 Therefore, the use of RFB in a standar-
dized MDR-TB regimen would be unwise in cases of known or
highly suspected MDR-TB and in the absence of individualized
and highly controlled in vitro testing. The use of RFB is also
likely to be confined to patients co-infected with HIV who are
receiving protease inhibitors. HIV-positive individuals in
Rwanda have access to free antiretroviral treatment with
the assistance of the Global Fund to Fight AIDS, TB, and
Malaria.
Apart from RFB, second-line drug resistance was low (KM,
ETH, PAS, and CLA). Resistance to fluoroquinolones as deter-
mined by OFX was moderate (4.3%), at a concentration of
1.0 mg/ml. This was similar to the result obtained for the
recent national survey comprising 701M. tuberculosis isolates
in Rwanda (data not shown). One of the three OFX-resistant
MDR-TB patients was newly diagnosed, another was a relapse
case, and one patient was a treatment failure (Table 1).
Although nearly half (47.2%) of all isolates were resistant to
streptomycin, the vast majority (98.6%) of MDR-TB isolates
from our study were sensitive to the second-line injectable
aminoglycosides. The same observation was made in Russia,7
and most probably can be explained by a difference in drug
targets. All aminoglycosides act by impairing protein synthesis
at bacterial ribosome. Half of known streptomycin-resistant
mutations are located in the rpsL gene encoding for the 12S
rRNA and to a lesser extent in the 16S rRNA gene at two
conserved loop domains (around nucleotides 530 and 912).13
Resistance-conferringmutations for amikacin and KM, are also
located in the 16S rRNA gene but around nucleotide 1400.13
With regard to combined second-line drug-resistance pro-
files per patient, the vast majority (91.3%) of MDR-TB cases
showed no resistance to the second-line drugs tested or only
resistance to RFB (81.2%). If you disregard the data on RFB
resistance, three cases showed second-line drug-resistance
to OFX only, one case to CLA and PAS, and one to KM and ETH.
No case of extensively drug-resistant TB (XDR-TB) was
detected, if defined as MDR-TB showing resistance to three
classes of second-line drugs (Centers for Disease Control and
Prevention14), or if defined as MDR-TB showing resistance to a
fluoroquinolone and an injectable drug (WHO15).
Despite the WHO guidelines for second-line drug testing
(WHO/CDS/TB/2001.288),16 standard recommendations onthe drug concentrations to be used for the various methods
andmedia currently applied for DSTofM. tuberculosis are still
lacking. Some inter-laboratory studies have made medium-
specific suggestions (Pfyffer et al.,17 Rusch-Gerdes et al.18),
but data are still scattered and international organized exter-
nal quality assessment is scarce. At themomentwe started this
study, we decided to use the second-line drug concentrations
that were installed and validated within the laboratory at that
time. For KM and RFB our concentrations are above those
recommended by Pfyffer et al. for BACTEC 460 and by Rusch-
Gerdes et al. for the comparable BACTEC MGIT 960 system
(20.0 vs. 5.0 mg/ml for KM; 1 vs. 0.5 mg/ml for RFB).17,18
Therefore, our results could represent an underestimation
of resistance, especially the low level resistance observed
with KM. However, these drugs are not freely available in
Rwanda and are not commonly used for treatment of diseases
other than TB, making acquired resistance to these drugs
unlikely. For ETH, our concentration (2.5 mg/ml) was in bet-
ween the previously recommended concentration of 1.25 mg/
ml for BACTEC 46017 and the recently recommended concen-
tration in BACTEC MGIT 960 (5.0 mg/ml).18 For OFX our con-
centration was half of that recommended (1.0 vs. 2.0 mg/ml)
with a possible risk of overestimating the drug resistance rate.
No significant difference in resistance rates was found
between new and previously treated cases, indicating that
the problem of resistance to second-line drugs is related both
to the spread of resistant strains and to the development of
resistance to these drugs during treatment, as evidenced by
the development of OFX resistance after inadequate treat-
ment (monotherapy).12
Most MDR-TB treatment programs have used individua-
lized regimens based on DST results. This strategy requires
ready access to reliable laboratory facilities and medical
specialists to integrate results and to prescribe tailored
regimens. Such resources are not available in many low-
income countries. An alternative strategy could involve
treating all MDR-TB with a standardized regimen based on
common DST profiles of prevalent MDR-TB strains.19 Our data
support a standardized approach of reasonable alternatives
to individualized treatment of MDR-TB in Rwanda. Compared
to the national survey, our convenience sample detected a
higher rate of MDR-TB cases (11.6% vs. 4.6% among all cases),
most probably due to the fact that we included more urban
areas. The over-representation of MDR-TB cases in this study,
however, most probably does not affect our finding of low
second-line drug resistance among MDR-TB, as resistance is
expected to be higher in urban settings where drugs in
general are more easily accessible.
Finally, in order to determine the value of rapid diagnosis
of MDR-TB and the relative merits of standardized regimens
compared to individualized treatment regimens for treating
MDR-TB in low-income countries such as Rwanda and the
Great Lakes Region, further prospective clinical trials are
needed. This is particularly important in the context of
increasing TB/HIV co-infection.Acknowledgments
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